Compare W W Grainger Inc (GWW) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
W W Grainger Inc vs Zimmer Biomet Holdings Inc — how do they compare? W W Grainger Inc trades at $1,290.05 (market cap $59.76B), while Zimmer Biomet Holdings Inc trades at $88.85 (market cap $16.95B). The key difference: W W Grainger Inc is far larger — about 3.5× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (1.08%). Which is the better fit depends on your goals — on Pluang, investors hold W W Grainger Inc for 25 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| GWW | ZBH | |
|---|---|---|
Market Cap | $59.76B | $16.95B |
Volume | 186,697 | 2,505,240 |
Sector | Industrials | Health |
52-Week High | $1.40K | $103.98 |
52-Week Low | $918.18 | $79.58 |
Typical Hold Time | 25 Days | 89 Days |
Enterprise Value | $61.96B | $24.02B |
Dividend Yield | 0.79% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
W.W. Grainger (GWW) trades at $1,263.51, down 0.94% on the day, amid a bearish technical signal. Recent earnings show mixed results with Q4 2025 missing estimates but Q1 and Q2 2026 beating expectations. The company maintains strong profitability with a net income margin of 9.92% and ROE of 47.92%, though valuation ratios like P/E of 32.34 appear elevated. Recent news highlights institutional buying and expansion efforts, including a new distribution center in Oregon and the acquisition of technology assets from Adroit Worldwide Media.
The outlook for GWW is cautiously optimistic, supported by earnings beats and solid fundamentals, but risks include high valuation and competitive pressures. Analyst consensus leans hold with a $1,310 price target, suggesting limited upside. Investors should weigh strong cash flow and dividend consistency against potential margin compression and market volatility.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About W W Grainger Inc
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
